Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in... It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.
- Mechanism
- Curator reviewed
AE-941(Neovastat) contains a component that specifically prevents the binding of VEGF (Vascular Endothelial Growth Factor) to its receptors. It inhibits gelatinolytic and elastinolytic activities for MMP-2, MMP-9, and MMP-12. The MMP's are often over expressed in tumors and play an important role in the degradation of the matrix that surrounds the cell (extracellular matrix), which allows tumor growth and invasion (metastasis). It also induces apoptosis (programmed cell death) which is an additional Anti angiogenic activity found in Neovastat.
- Primary indication
- Investigated for use/treatment in kidney cancer, lung cancer, macular degeneration, multiple myeloma, prostate cancer, and psoriasis and psoriatic disorders.Curator reviewed
- Code names
- AE-941
Resolves to
What you can answer from here — as of July 18, 2023
Which drugs share a target with Neovastat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account